Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Future Oncol
; 17(23): 3037-3050, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-34044594
Lay abstract Head and neck cancer include tumors that develops in the mouth, throat, nose, salivary glands, oral cancers or other areas of the head and neck. When this cancer returns or spreads to another part of the body, systemic chemotherapies are often used with the goal of prolonging survival. Immunotherapy has emerged as a new approach to treat head and neck cancer by using the body's own immune system to kill cancer cells. The purpose of this study was to better understand the use of immunotherapies in patients with head and neck cancer after the cancer has returned or spread to another part of the body. The study showed that immunotherapies were commonly used and resulted in fewer treatment discontinuations in comparison to other systemic chemotherapies. These results support the use of immunotherapies in this patient population.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antineoplásicos Imunológicos
/
Carcinoma de Células Escamosas de Cabeça e Pescoço
/
Neoplasias de Cabeça e Pescoço
/
Recidiva Local de Neoplasia
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article